Inovio reports early flu vaccine results; Supercomputer Watson donates winnings to malaria research;

> Inovio Pharmaceuticals ($INO) said a Phase I trial of its avian flu vaccine SynCon generated HAI titers against six different strains of H5N1, presenting a possible development path for a universal flu vaccine. Inovio release

> Bionor Pharma's universal influenza vaccine, Vacc-Flu, reduced serious flu symptoms by 25% in an animal study. Bionor release

> The U.S. is reaching out to Australia's Commonwealth Scientific and Industrial Research Organization to help with development of vaccines to combat bioterrorism. Article

> 10 promising therapeutic vaccines to watch. Article

And Finally... IBM, which developed JEOPARDY! champion Watson, is donating half of the supercomputer's $1 million in winnings to Scripp Research Institute to conduct malaria research. Release

Suggested Articles

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.

As top players race to deliver COVID-19 vaccines, Russia approved a locally developed shot based on skimpy data. Experts called it a political stunt.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan